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Abstract  
Background: Bayesian adaptive designs can be more efficient than traditional methods for multi-arm 
randomised controlled trials. The aim of this work was to demonstrate how Bayesian adaptive 
designs can be constructed for multi-arm phase III clinical trials and assess potential benefits that 
these designs offer. 
Methods: We constructed several alternative Bayesian adaptive designs for the Collaborative Ankle 
Support Trial (CAST), which was a randomised controlled trial that compared four treatments for 
severe ankle sprain. These incorporated response adaptive randomisation, arm dropping, and early 
stopping for efficacy or futility. We studied the Bayesian designs’ operating characteristics via 
simulation. We then virtually re-executed the trial by implementing the Bayesian adaptive designs 
using patient data sampled from the CAST study to demonstrate the practical applicability of the 
designs. 
Results: We constructed five Bayesian adaptive designs, each of which had high power and recruited 
fewer patients on average than the original design’s target sample size. The virtual executions 
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showed that most of the Bayesian designs would have led to trials that declared superiority of one of 
the interventions over the control. Bayesian adaptive designs with RAR or arm dropping were more 
likely to allocate patients to better performing arms at each interim analysis. Similar estimates and 
conclusions were obtained from the Bayesian adaptive designs as from the original trial. 
Conclusions: Using CAST as an example, this case study found that Bayesian adaptive designs can be 
constructed for phase III multi-arm trials using clinically relevant decision criteria. These designs 
demonstrated that they can potentially generate earlier results and allocate more patients to better-
performing arms. We recommend the wider use of Bayesian adaptive approaches in phase III clinical 
trials. 
Trial registration: CAST study registration ISRCTN, ISRCTN37807450. Registered 25 April 2003, 
retrospectively registered. http://www.isrctn.com/ISRCTN37807450 
Keywords: Bayesian adaptive design; interim analysis; multi-arm trial; response adaptive 
randomisation; arm dropping; monitoring; orthopaedic; emergency medicine; randomised 
controlled trials; phase III 
 
Background 
The traditional phase III trial design involves randomising patients to one of two arms, often with 
equal probability of allocation. The sample size is calculated using frequentist methods, which 
involve assuming a particular treatment effect and type I error rate to achieve a particular level of 
power. Phase III trials generally require large sample sizes, have long duration, and many are 
declared “unsuccessful” due to a perceived lack of difference between treatment arms [1]. For 
decades, statisticians have been developing more efficient methods for designing clinical trials, yet 
the majority of trials continue to use traditional methods. 
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Adaptive trial designs have the potential to allow trials to answer their questions more efficiently, 
particularly for multi-arm trials, by enabling key operational components to be altered based on 
analyses of accumulated data. All possible decisions and adaptations must be specified before the 
trial commences, as well as the decision criteria. Potential adaptations in multi-arm trials include: 
stopping early for high probability of efficacy or futility; arm dropping; altering the randomisation 
probabilities between arms, known as outcome or response adaptive randomisation.  
When implementing response adaptive randomisation (RAR), the probability of being assigned to 
each treatment arm is not fixed and may be altered at each interim analysis based on the accrued 
outcome data. For instance, the probability of being assigned to an arm could increase when the 
accumulated outcome data suggest that the treatment arm is superior, and thus maximises the 
number of patients receiving the better treatment. Arm dropping may be performed in multi-arm 
trials to remove an arm that does not appear to be effective. There is no globally optimal method for 
patient allocation in multi-arm trials and the choice of method depends on the aims and setting of 
the trial, as some allocation methods may be more practical than others. It is also advantageous to 
have planned interim analyses so that if the treatment effect is large and there is a high probability 
of claiming superiority, or conversely, if the treatment effect is very small or non-existent, then the 
trial can be stopped early. 
Further advantages can be gained by designing a trial within the Bayesian framework. The Bayesian 
approach allows previous information on the treatment effect or response to be incorporated into 
the design via the prior distribution. The prior is updated as data are observed in the trial to become 
a posterior distribution. The posterior distribution is calculated at each interim analysis to 
incorporate current information. The posterior distribution provides probabilistic statements about 
the values of various measures of interest, such as the treatment effect, adverse event rates, or arm 
with the maximum response. For instance, one could obtain from the posterior distribution the 
probability that the relative risk is less than 1. The posterior may be used to drive the decisions at 
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the interim analyses, such as whether to stop early for efficacy or drop an arm. The prior and 
posterior distributions also account for uncertainty in the unknown values of the measures of 
interest. 
Bayesian adaptive designs have often been used in early phase trials, but there are few published 
phase III trials that have used a Bayesian adaptive approach from the design phase (e.g., [2-4]). In 
this work we will explore how Bayesian adaptive designs could be constructed for an emergency 
medicine (orthopaedic) multi-arm trial and examine the potential benefits that these designs may 
offer. 
 
Methods 
Case Study 
The Collaborative Ankle Support Trial (CAST; [5-7]) was a pragmatic, individually randomised 
controlled trial (RCT) that compared the effectiveness of three types of mechanical ankle support 
with tubular bandage (control) for patients with severe ankle sprains. The three interventions were: 
Aircast® ankle brace, Bledsoe® boot, and below-knee cast. Patients above 16 years with an acute 
severe ankle sprain who were unable to bear weight, but had no fracture, were recruited from eight 
emergency departments in England. The primary outcome was the quality of ankle function at 12 
weeks post-randomisation as measured by the foot- and ankle-related quality of life subscale (QoL) 
of the Foot and Ankle Outcome Score (FAOS; [8]). The FAOS QoL subscale ranges from 0 (extreme 
symptoms) to 100 (no symptoms). Randomisation occurred 2-3 days after the initial visit to the 
emergency department at a follow up clinical visit.  
 
The CAST study was designed using traditional/frequentist methods and had a fixed design. A target 
sample size of 643 patients was required to provide more than 90% power to detect an absolute 
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difference of 8-10 in the FAOS QoL, assuming a type I error rate of 5% and 20% loss to follow up. The 
minimal clinically important difference (MCID) in the FAOS QoL subscale was specified as a change 
between 8 and 10. The aim of this trial was to identify the best arm for treatment of severe ankle 
sprains to assist in recovery.  
A revised sample size was calculated by the Data Monitoring Committee (DMC) after 100 
participants were recruited and an estimated target of 480-520 participants provided at least 80% 
power to detect the MCID, assuming a type I error rate of 5% [7]. 
The CAST study randomised 584 patients: 144 to tubular bandage, 149 to Bledsoe® boot, 149 to 
Aircast® brace, and 142 to below-knee cast. At 12-weeks post-randomisation, the FAOS QoL was 
estimated to be 53.5 (95% CI 48.4, 58.6) for the tubular bandage arm. Clinically important benefits 
were found at 12 weeks in the FAOS QoL with the below-knee cast compared to the tubular bandage 
(mean difference 8.7; 95% CI 2.4, 15.0), and with the Aircast® brace compared to the tubular 
bandage (mean difference 8; 95% CI 1.8, 14.2). The Bledsoe® boot did not offer a clinically important 
difference over the tubular bandage (mean difference 6.1; 95% CI 0, 12.3). These estimates were 
adjusted for baseline FAOS QoL (standardised using the median as the centre), as well as age and 
sex. 
 
Potential adaptations for Bayesian designs 
In our Bayesian adaptive designs we want to quickly identify the best performing intervention arm. A 
secondary aim is to deliver the best therapy to patients within the trial. Our designs will reward 
better performing arms and remove poorly performing arms. The Bayesian adaptive designs were 
constructed as one-sided superiority studies as we were interested in demonstrating improvement 
over control. 
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To achieve this, the following types of adaptations will be explored: RAR, arm dropping and early 
stopping for either efficacy or lack of benefit (futility). Below we describe how these adaptive 
features have been incorporated into the Bayesian designs, as well as the rules with which these 
adaptations could be implemented. The rules for implementing these adaptations were determined 
based on the input of clinicians, criteria used in previous studies (e.g., [9, 10]) and the results of 
simulations which explored a range of clinically relevant values. Decision thresholds were also 
chosen to optimise probability of trial success, average number of patients randomised, and the 
proportion of patients randomised to the best therapy. Stopping boundaries were also chosen to 
ensure the simulated one-sided type I error rate was <2.5%.  
The Bayesian adaptive designs were constructed by a statistician (EGR) who was independent of 
CAST and was blind to the data and results of the trial until the designs’ operating characteristics had 
been simulated. The designs were constructed using the CAST protocol and discussions were held 
with CAST investigators (SEL and EW) to derive the design parameters and determine how the 
adaptive features could be incorporated to ensure the designs were practically feasible. 
 
Interim analysis schedules and candidate designs 
We investigated a range of interim analysis schedules where adaptations could be performed every 
50, 100 or 200 patients due for their primary outcome assessment (12 weeks post-randomisation). 
We note that operationally, fewer interim analyses are typically preferred. We found that 
performing RAR or arm dropping more frequently increased the probability of trial success and 
decreased the sample size (results not shown), and so we only present the adaptive designs that 
performed RAR or arm dropping every 50 patients. Assessment of early stopping for efficacy or 
futility was performed every 200 patients due for their primary outcome assessment in each 
adaptive design. This was performed less frequently than RAR/arm dropping to control the type I 
error and reduce operational complexity, particularly for the monitoring committees who may not 
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need to meet for randomisation probability updates or arm dropping decisions. A fixed Bayesian 
design was also investigated for comparative purposes. The Bayesian designs explored are described 
in Table 1.  
 
Table 1. Bayesian adaptive designs explored for CAST study 
Design Interim analysis 
schedulea 
Arm allocationb Control allocation Early stopping 
1 None 1:1:1:1 Equal to other arms None 
2 Every 200 patients 1:1:1:1 Equal to other arms Efficacy or 
futility every 
200 patients 
3 Every 50 patients Arm dropping assessed 
at each interim analysis 
Equal to other arms Efficacy or 
futility every 
200 patients 
4 Every 50 patients RAR at each analysis  Matched to best intervention arm Efficacy or 
futility every 
200 patients 
5 Every 50 patients RAR at each analysis Fixed at 40% 
 
Efficacy or 
futility every 
200 patients 
6 Every 50 patients RAR at each analysis No designated control; tubular bandage 
is treated as an intervention arm  
Efficacy or 
futility every 
200 patients  
aAt number patients due for primary outcome follow up (at 12 weeks post-randomisation); b RAR = Response adaptive randomisation 
 
Response adaptive randomisation (RAR) 
Prior to the first interim analysis, equal randomisation (ER) was used. At each interim analysis the 
randomisation probabilities were updated to be proportional to the posterior probability that the 
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arm was the best intervention arm. The randomisation probabilities were then adjusted to sum to 
one. Enrolment was suspended to arms that had a randomisation probability < 0.1. The suspended 
arm(s) could re-enter the randomisation allocation at later interim analyses if the randomisation 
probabilities crossed above the threshold.  
We explored designs that employed different approaches for control arm allocation in RAR. First we 
simulated trials in which the control allocation was matched to the intervention arm with the highest 
probability of allocation. This maximises the power for the comparison of the best arm to the 
control. We then assumed a fixed control allocation of approximately 40%, which may be preferred 
for logistical reasons. Various fixed allocations for the control were explored via simulation and the 
allocation of 40% was chosen based on the resulting operating characteristics (results not shown). A 
similar optimal control allocation was found in [11] for fixed designs. Finally, we explored a design in 
which the “control” arm (tubular bandage) allocation varied according to its probability of being the 
best arm. In this design, all arms were considered as “interventions” and recruitment to the tubular 
bandage arm could be suspended if it had a low probability of being the best arm (as for the other 
arms). 
 
Arm dropping  
We also investigated the use of permanent arm dropping, where an arm could be dropped if it had a 
low posterior probability (<10%) of being the best arm at an interim analysis. In the arm dropping 
designs, the control arm could not be dropped, but any intervention arm could be dropped. If an 
arm was dropped, the block size was reduced, but the overall maximum sample size was kept the 
same. Equal allocation was used for the remaining arms.  
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Early stopping for efficacy or futility 
Early stopping for efficacy and futility was assessed at interim analyses performed when 200, 400 
and 600 patients were due for their primary outcome assessment visit (12 weeks post-
randomisation) in all adaptive designs.  
For most of the adaptive designs explored (Designs 2-5, Table 1), we allowed early stopping for 
efficacy if there was a fairly large posterior probability of there being a MCID of 8 between the best 
intervention arm and the tubular bandage in the primary outcome (equation 1) and if there was a 
high probability (>90%) that the arm is the best arm (equation 2), i.e., 
Pr(𝜃𝐵𝑒𝑠𝑡 − 𝜃𝑡𝑢𝑏𝑢𝑙𝑎𝑟 𝑏𝑎𝑛𝑑𝑎𝑔𝑒  >  8) >  𝑆𝑖  (1) 
and Pr(𝐵𝑒𝑠𝑡𝑡) >  0.9                                (2) 
where 𝜃𝐵𝑒𝑠𝑡 and 𝜃𝑡𝑢𝑏𝑢𝑙𝑎𝑟 𝑏𝑎𝑛𝑑𝑎𝑔𝑒 are the estimates of the FAOS QoL scores at 12 weeks for the best 
intervention arm and the tubular bandage, respectively; and 𝑆𝑖 is the stopping boundary for efficacy 
at interim analysis i for the comparison of the best arm to the tubular bandage. Pr(𝐵𝑒𝑠𝑡𝑡) is the 
probability that arm t (t = boot, brace, below-knee cast) is the best arm. 
Both criteria (1) and (2) must be met for the trial to stop early for efficacy. The Si values used were 
0.75, 0.7, and 0.6 for interim analyses performed at 200, 400 and 600 patients due for their primary 
outcome visit, respectively. These values were used for Designs 2-5 (Table 1).  The stopping 
boundaries were chosen to ensure acceptable power and were clinically relevant values.  
We also defined success criteria for the trial at the final analysis to enable the type I error and power 
to be calculated and compared across the designs. At the final analysis, the trial was declared 
successful for Designs 1-5 if: 
Pr(𝜃𝐵𝑒𝑠𝑡 − 𝜃𝑡𝑢𝑏𝑢𝑙𝑎𝑟 𝑏𝑎𝑛𝑑𝑎𝑔𝑒  >  8) >  0.5  (3) 
10 
 
If this criterion was not met then the trial was declared unsuccessful. 
For Designs 2-5, early stopping for statistical futility was based on having a small posterior 
probability that the best arm is better than the tubular bandage, i.e., 
 Pr(𝜃𝐵𝑒𝑠𝑡 > 𝜃𝑡𝑢𝑏𝑢𝑙𝑎𝑟 𝑏𝑎𝑛𝑑𝑎𝑔𝑒 ) < 0.05   (4) 
 
Design 6 (Table 1) used RAR where allocation to the tubular bandage arm could vary according to its 
probability of being the best arm. This design focussed on identifying the best arm overall with a 
high probability rather than looking for a MCID between intervention arms and tubular bandage. 
Therefore, early stopping for efficacy or futility was based on the probability of being the best arm, 
evaluated at the best arm. That is, Pr(𝐵𝑒𝑠𝑡𝑡=𝑏𝑒𝑠𝑡 𝑎𝑟𝑚). If this probability was <0.1 at interim 
analyses performed at 200, 400 or 600 patients, then the trial was stopped early for futility. If this 
probability was >0.975 at 200 patients, >0.95 at 400 patients, or >0.925 at 600 patients, then the 
trial was stopped early for efficacy. The trial was deemed to be successful at the final analysis if this 
probability was >0.9.  
 
Simulation Settings 
Simulations of the designs were performed in FACTS (version 6.2 [12]) so that the operating 
characteristics of each design could be studied.  We used a recruitment rate of 5 patients/week and 
assumed it took 12 weeks to reach this recruitment rate. We also explored recruitment rates of 25 
and 56 patients/week (assuming it took 12 weeks to reach these recruitment rates; see Appendix). 
We used the same dropout rate that the original study design assumed (20%). The posterior 
distribution was estimated for each treatment arm, and the FAOS QoL estimates at 12 weeks were 
adjusted for the baseline scores. Details on the model and priors used are given in Additional File 1. 
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Prior to the start of the CAST study there was uncertainty regarding the effect size and FAOS QoL 
values, and so we simulated a range of different true effect size scenarios for each design. The 
different scenarios explored for the primary outcome in each arm are given in Table 2. 
Table 2. Scenarios explored for Bayesian designs 
Scenario Control/tubular 
bandage FAOS QoL 
Boot FAOS QoL Brace FAOS QoL Below-knee Cast 
FAOS QoL 
Null 50 50 50 50 
One works, 10 more 50 50 50 60 
One works, 5 more 50 50 50 55 
Better, Best 50 55 60 65 
One worse, others work 50 45 55 60 
All work, two similar 50 55 60 60 
 
We simulated 10,000 trials for each scenario in Table 2 for each design. The type I error was 
estimated using the proportion of simulations that incorrectly declared the trial to be successful 
when no difference was present in the true primary outcome scores (null scenario above). The 
power was calculated as the proportion of simulations that declared the trial to be successful, when 
at least one treatment was superior in the true FAOS QoL score.  
We wanted to accurately estimate the response of the arm that was chosen to be the best. Some 
studies have shown that RAR can lead to a larger estimation bias compared to ER (e.g., [13]). To 
quantify bias in the estimates of the best arm responses, we use the mean square error (MSE) of 
estimation, where the expectation is taken over the space of successful trials.   
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Virtual Re-execution of Designs 
A virtual re-execution of the CAST study was performed by implementing the Bayesian designs using 
the CAST data to illustrate the application and potential benefits of the Bayesian adaptive designs on 
a real-world trial. We maintained the original enrolment dates for the CAST patients in the re-
execution. Since Designs 3-6 incorporated arm dropping or RAR every 50 patients, the required 
allocations for these designs are unlikely to match the allocations that actually occurred in the CAST 
data. Therefore, at each interim analysis we used the updated randomisation probabilities to obtain 
allocations for the next 50 patients and then randomly sampled (with replacement) a CAST patient 
for the re-execution dataset that had a matching treatment allocation and was randomised into the 
original CAST study within ±6 weeks of the re-execution enrolment date. To avoid bias, for each 
design the trial was virtually re-executed 1000 times by drawing data from the CAST dataset and 
performing the interim analyses.  A flow diagram of the re-sampling and interim analysis process for 
Designs 3-6 is given in Figure 1. Further details are given in Additional File 1. 
Designs 1 and 2 had fixed arm allocation probabilities throughout the trial, and so we could use the 
actual CAST data in the virtual executions of these designs without the need for re-sampling. The 
results of these analyses are displayed in Additional File 2. We also used a simplified version of the 
process described in Figure 1 to resample many datasets from the CAST data to virtually execute 
Designs 1 and 2 so that their results were more comparable to those from Designs 3-6. This also 
enabled us to examine potential gains in efficiency over a range of datasets. 
Since the CAST study only recruited 584 patients we were unable to perform all planned interim 
analyses. The last interim analysis occurred at 400 patients for Design 2 and 550 patients for Designs 
3-6. The final analysis occurred once follow-up data had been collected for the 584 patients. The re-
executions were performed in R (version 3.5.0; R Foundation for Statistical Computing) and the rjags 
package [14] was used to perform the Bayesian analyses. We used a similar approach to [15] to 
perform the virtual re-executions and re-sampling of patients. 
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Figure 1. Flow diagram showing the process for the virtual re-execution of Designs 3-6. Response adaptive 
randomisation or arm dropping was performed every 50 patients until the final analysis (at N=584). Early 
stopping for efficacy or futility was assessed every 200 patients. The process depicted in this figure was 
repeated 1000 times. 
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Results  
Operating characteristics for Bayesian designs 
Select operating characteristics for the Bayesian designs are presented in Table 3 and Figure 2. 
Further operating characteristics are given in Additional File 2. Boxplots of the distribution of the 
allocations to the control and best arm for each scenario across the 10, 000 simulations are 
presented in Figure 3. The effect of using a faster recruitment rate is summarised in Additional File 3. 
The Bayesian adaptive designs generally offered a decreased average sample size and increased 
power/probability of trial success across the scenarios explored, compared to the Bayesian fixed 
design. There was little variation in the sample size for the null scenario across the Bayesian designs, 
and the simulated type I error was approximately 0 for the majority of designs under this scenario. 
There was also little variation in the sample size and probability of having a successful trial when a 
difference of 5 was assumed between the tubular bandage and the best arm for each design, apart 
from Bayesian Design 6, which had a slightly smaller average sample size and a higher probability of 
having a successful trial.  
Bayesian Design 6 had the lowest average sample size and highest probability of success for the 
“One works, 10 more” and “One worse, others work” scenarios; the other adaptive designs had 
similar average sample sizes and probability of trial success and also offered improvement over the 
fixed design for these scenarios. All designs had high probability of success for the “Better, Best” 
scenario and the average sample size was reduced by incorporating interim analyses (Designs 2-6). 
Bayesian Design 6 did not perform as well as the other designs for the “All work, two similar” 
scenario in terms of the probability of trial success since one arm was not clearly superior. This 
decreased the probability of being the best arm and so the trial was deemed to be “unsuccessful” in 
30% of the simulated trials. 
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We also simulated a scenario where all the intervention arms were inferior to the tubular bandage 
arm (FAOS 50, 45, 45, and 45 for tubular bandage, boot, brace, and below-knee cast, respectively). In 
Designs 1-5, all of the simulated trials were declared to be unsuccessful at the final analysis for this 
scenario and 41.72-58.91% of the simulated trials stopped early for futility (Designs 2-5). For this 
scenario Design 6 had similar results to the “One arm works, 5 more” scenario since it did not 
consider the tubular bandage to be a control arm here and had one arm superior by an FAOS of 5. 
The probability of having a successful trial and average sample sizes were similar between Bayesian 
Designs 3-5 across the scenarios. Design 6 had the lowest average sample size and highest 
probabilities of success when a treatment effect was present and one arm was clearly superior. 
Design 6 did not perform as well as the other adaptive designs when two arms offered a similar 
improvement in the FAOS QoL. Design 6 had different objectives and decision criteria to the other 
Bayesian designs, and so care should be taken when choosing a preferred design since the designs 
are tailored to the aims of the investigators. 
Due to the lack of successful trials in the null and “one arm works, 5 more” scenarios for the majority 
of designs, the MSE was not calculated for these scenarios. The adaptive designs tended to have 
slightly higher MSE than the fixed design, apart from Design 6 which had lower MSE. RAR and arm 
dropping designs had lower MSE compared to the design that just had early stopping for efficacy or 
futility (Design 2).  
For each design, the correct selection of the best arm was made in approximately all of the 
simulated trials, where at least one arm was superior to control (data not shown). From Table 3 and 
Figure 3, it can be seen that, on average, more allocations were given to the best arm under designs 
that incorporated RAR or arm dropping when at least one arm was superior. Equal allocation to the 
treatment arms was achieved in the null scenario for these designs. Design 6 tended to allocate the 
highest proportion of patients to the best arm, followed by Design 5. RAR with control matched to 
best arm (Design 4) tended to have similar allocations to the design that used permanent arm 
16 
 
dropping (Design 3). The designs with RAR or arm dropping (Designs 3-6) had a fairly large variation 
in their allocations to the best arm and the control, and were quite often skewed in their 
distribution. For Design 3, the proportion of arm drops was low for the best arm and high for the 
other arms (Additional File 2). 
[Table 3 here] 
 
Figure 2. Average sample sizes (left column) and probability of trial success (right column) for each design. Each row 
represents a different scenario: a) and b) “Null” scenario; c) and d) “One works, 10 more”; e) and f) “One works, 5 more”; 
g) and h) “Better, Best”; i) and j) “One worse, others work”; k) and l) “All work, two similar”. The type I error is represented 
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in Figure 2(b). The power is given in Figures 2 (d), (f), (h), (j), (l). 
 
 
Figure 3. Allocations across 10,000 simulated trials for tubular bandage (left column) and best arm (right column). Each 
design is represented on the x-axis in each figure and each row represents a scenario: a) and b) “One works, 10 more”; c) 
and d) “One works, 5 more”; e) and f) “Better, Best”; g) and h) “One worse, others work”; i) and j) “All work, two similar” 
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Virtual Re-execution of designs  
Table 4 presents a summary of the virtual re-execution of the CAST study under each Bayesian 
design across the 1000 trials that resampled the CAST study data. 
[Table 4 here] 
The results of the re-executions show that the Bayesian adaptive designs recommended early 
stopping for efficacy in 7.6-25.9% of trial re-executions, with the most frequent early stopping 
occurring in Design 2 which had fixed allocations and only allowed for early stopping of the trial. 
None of the trial re-executions recommended early stopping for futility, since all of the interventions 
performed better than the tubular bandage. At the final analysis for Designs 1-5, 83.5-89.4% of the 
trials were declared successful. Design 6, where decisions were based on the probability of being the 
best arm, had a low proportion (23%) of trials that were declared successful at the final analysis. This 
is due to the fact that the brace and below-knee cast had similar primary outcome scores and both 
performed well compared to the other arms. Thus, one arm was not often declared superior with a 
high probability. For each of the Bayesian designs, the below-knee cast was most frequently 
declared the best arm at the final analysis in the re-executions and thus had the same conclusion as 
the original trial.  
The medians of the posterior estimates for the treatment effects over the 1000 re-executions were 
generally similar to the original frequentist analysis estimates. Designs 4 and 5 (RAR with control 
allocation matched to best arm and RAR with fixed control allocation, respectively) had slightly lower 
estimates of the mean difference between Bledsoe boot and tubular bandage. Design 6 had slightly 
higher estimates of the mean difference between the ankle brace and tubular bandage, and also 
between the below-knee cast and tubular bandage. One should also bear in mind that the re-
executions were performed on re-sampled data from the original dataset, and so the estimates are 
likely to vary slightly. 
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Further summaries of the results and randomisation allocations at each interim analysis for each 
adaptive design are given in Additional File 4. These results show that the randomisation 
probabilities differed between Bayesian designs 4-6 at each interim analysis, and that these RAR 
designs often had quite different allocations to the CAST study, depending on which arm was “the 
best” at that interim analysis. 
Discussion 
Summary 
In this study we have demonstrated how Bayesian adaptive designs can be constructed for Phase III 
multi-arm RCTs. Using an orthopaedic trial as a case study, we outlined the process involved in 
constructing the designs, described the adaptive schemes and stopping rules employed, and 
demonstrated the designs’ behaviour through their operating characteristics across a range of 
scenarios. We also performed virtual executions of the Bayesian designs using data from the CAST 
study to demonstrate the decisions that would be made using the Bayesian designs and the trial 
data. Through use of the Bayesian adaptive approach we were able to make decisions about 
whether to stop the trial early based on the probability of having a MCID, update the randomisation 
allocations according to the probability of being the best arm, and suspend recruitment to arms that 
had a low probability of being the best.  
Based on the operating characteristics, the use of Bayesian adaptive designs for this case study 
generally increased the power and decreased average sample size compared to a fixed design. Use 
of RAR or arm dropping offered increased power compared to an adaptive design that only allowed 
for early stopping when it was assumed that one arm offered a MCID. All designs had low type I 
error and high probabilities to detect a MCID in at least one arm, when it was assumed that a MCID 
was truly present. The correct selection of the best arm was made in approximately all of the 
simulated trials, where at least one arm was superior to control. Use of RAR or arm dropping 
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produced simulated trials that gave more allocations to the best arm when at least one arm was 
superior. Equal allocation occurred when the arms had approximately the same primary outcome 
scores.  
Design 6, whose decisions were made based on the probability of being the best arm, typically 
produced the lowest average sample size and highest power when one arm was assumed to be 
superior. However, this design did not perform well when two arms showed a similar improvement 
compared to the other arms. Design 6 had different objectives and decision criteria to the other 
Bayesian designs, and so care should be taken when choosing a preferred design since the designs 
are tailored to the aims of the investigators. 
The virtual executions of the Bayesian designs using the CAST data showed that early stopping for 
efficacy only occurred in a small proportion of trials and that no trials stopped early for futility. At 
the final analysis >80% of the trials were declared successful in the 1000 executions of Designs 1-5. 
When Design 6 was executed 1000 times using the trial data, only 23% of the trials were declared 
successful at the final analysis, since both the brace and below-knee cast performed similarly well 
and a “best arm” was not declared with a high probability. A benefit of Design 6 was that the tubular 
bandage arm, which was the control arm in the other designs, had smaller allocation probabilities 
which allowed more allocations to better performing arms. The below-knee cast was most often 
declared the best arm at the final analysis in the re-executions, and so the Bayesian designs led to 
the same conclusion as the original trial.  
The decisions made at the interim and final analyses of the Bayesian designs were driven by the 
primary outcome. We did not incorporate other outcomes and are not intending that the 
conclusions generated in this re-execution be used to inform clinical practice or to alter the 
conclusions of the original study.  
 
21 
 
Limitations 
Adaptive designs have great promise for producing trials with better operating characteristics, but 
present a number of practical challenges. Korn and Freidlin [16] provide a summary of some of the 
advantages and disadvantages of different adaptive design elements.  
Adaptive designs require a larger amount of work to build and evaluate potential designs, compared 
to fixed designs, and may take more effort to obtain approval from review boards. Adaptive designs 
can also be more complicated to implement. Performance of the interim analyses and making the 
required adaptations is dependent on being able to collect, enter, clean and analyse data in a timely 
manner, and alter the randomisation system with ease. This requires the trial management team, 
statisticians, programming teams and trial treatment providers/intervention suppliers to be 
responsive to changes that need to be made. These rapid changes may not be possible in all trial 
settings. 
The interim analyses also need to be adequately spaced to allow time for DMCs and Trial Steering 
Committees (TSCs) to meet. Statistically, more frequent interim analyses generally produce better 
operating characteristics for designs that use RAR or arm dropping (e.g., [17]), but frequent interim 
analyses may not always be practical. The DMC/TSC may not necessarily need to meet for every 
interim analysis, e.g., for RAR adaptations, but would need to meet for stopping decisions. 
The types of adaptations that can be made to multi-arm trials are situation-dependent. RAR presents 
difficulties in being able to anticipate and arrange for the delivery of treatments. The original CAST 
study design, which had fixed allocations, allowed the supply of treatment arms (including the 
supply of staffing) to be planned more easily than a design with RAR would. RAR may not always be 
possible due to restrictions on resources for delivering the treatments or delays in collecting the 
primary outcome data. Closure of arms may be practically easier to achieve. Whilst early stopping of 
trials may have benefits for funding agencies, academic trial investigators often do not wish to 
terminate trials early, due to potential loss of research income and staff retention. Changes in 
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funding models are likely to be required to fully take advantage of innovation in trial design, such as 
a minimum study time funded with a mechanism to release funding if full study time is required.  
Additionally, trials that stop early may have little information on the long-term effects of treatment 
or on secondary outcomes, and are likely to produce less precise estimates of the treatment effects. 
The use of RAR remains controversial and some of its properties are not well understood by 
clinicians. RAR has its greatest potential in multi-arm trials but has limited usefulness in two-armed 
trials [18, 19]. Adaptive designs are more susceptible to changes in patient population over time. 
Designs with RAR are robust to moderate changes in population (see [20]), but adaptive designs are 
not appropriate if the patient population changes dramatically during the trial. When evaluating 
adaptive designs, simulation is required to illustrate the operating characteristics and potential 
benefits, and investigate potential biases introduced by each adaptive feature.   
Fairly short follow-up times are required for adaptive designs to offer improved efficiency. Adaptive 
designs are difficult to implement for very fast recruitment rates, particularly for studies that have 
relatively longer follow-up periods, since less information will be available at each interim analysis. 
This poses difficulties for phase III trials since the primary outcome is often based on long-term 
measures, and it may be difficult to design adaptive trials without extending the time frame of 
recruitment to allow for the interim analyses and potential adaptations to occur. Thus there may be 
a trade-off in reduced sample size but increased recruitment time (at a slower recruitment rate) for 
some adaptive trial design contexts. 
In this work we virtually executed each of the proposed Bayesian designs using trial data to illustrate 
their practical applicability. However, in reality, one design would have been chosen and 
implemented, depending on its operating characteristics, practical restraints and the aims of the 
trial. When virtually executing the designs that incorporated arm dropping or RAR, resampling from 
the original trial data was required to obtain the required randomisation allocations. This may lead 
to an underestimation of the uncertainty in the results [10]. We addressed this by re-executing the 
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CAST study 1000 times and resampled patients within each trial. If different datasets had been used, 
different conclusions may have been obtained using these designs.  
We did not simulate the decision making process of a DMC/TSC. We have assumed that the decision 
making process was driven by the primary outcome, but the DMC/TSC would also examine safety 
data and any relevant external evidence. Whilst the role of these committees is to ensure that the 
study protocol is accurately followed, they may also need to make deviations to ensure patient 
safety. For example, RAR may recommend increasing the allocation probability to an arm that has a 
higher rate of adverse events – an event that was not accounted for in the RAR algorithm. 
Alterations to the previously defined adaptations can lead to unknown operating characteristics. 
The Bayesian adaptive designs were constructed as one-sided superiority studies, whereas the 
original CAST study was a two-sided trial.  We were interested in demonstrating improvement over a 
much cheaper control, and felt that a DMC would be unlikely to continue enrolment into a poorly 
performing comparator just to show it is worse. Under most of our Bayesian adaptive designs, if an 
intervention arm performed poorly it would be dropped or have a very low probability of allocation. 
Harm may or may not be reflected in the FAOS QoL score, but the DMC could intervene if any arms 
were causing harm. 
The designs presented here are situation specific and have been tailored to the clinical situation and 
aims of the CAST study. The definition of a successful trial and the level of sufficient evidence 
required to make decisions will differ between researchers and stakeholders, and will depend on the 
consequences of the actions that may be taken. The designs and findings from this work will not 
generalise to all phase III randomised controlled trials, but similar approaches can be used to 
construct Bayesian adaptive designs. We recommend that simulations are used to study the impact 
of each type of adaptive component on the operating characteristics when constructing Bayesian 
adaptive designs for multi-arm trials.  
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Conclusions 
To enable phase III trials to achieve their aims, more efficient methods are required. Innovation in 
clinical trial design is extremely important as it can potentially improve the efficiency, quality of 
knowledge gained, cost and safety of clinical trials. In this work we have demonstrated how Bayesian 
adaptive trials can be designed and implemented for multi-arm phase III trials. Using a published 
example from orthopaedic medicine, we highlight some of the benefits of these designs, particularly 
for multi-arm trials. 
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Table 3. Operating characteristics for Bayesian designs for CAST study 
Designa  Proportion 
stopping 
early for 
efficacy 
Proportion 
stopping 
early for 
futility 
MSE Mean 
proportion 
allocated to 
control 
Mean 
proportion 
allocated 
to boot 
Mean 
proportion 
allocated 
to brace 
Mean 
proportion 
allocated 
to below-
knee cast 
Design 1 Fixed design  
Null (50, 50, 50, 50) NA NA NA 0.25 0.25 0.25 0.25 
One arm works, 10 more (50, 50, 
50, 60) 
NA NA 2.77 0.25 0.25 0.25 0.25 
One arm works, 5 more (50, 50, 50, 
55) 
NA NA NA 0.25 0.25 0.25 0.25 
Better best (50, 55, 60, 65) NA NA 3.29 0.25 0.25 0.25 0.25 
One worse, others work (50, 45, 55, 
60) 
NA NA 2.96 0.25 0.25 0.25 0.25 
All work, two similar (50, 55, 60, 
60) 
NA NA 3.39 0.25 0.25 0.25 0.25 
        
Design 2 Interim analysis every 200 patients, early stopping for efficacy or futility 
Null (50, 50, 50, 50) 0.0063 0.0063 NA 0.25 0.25 0.25 0.25 
One arm works, 10 more (50, 50, 
50, 60) 
0.732 0.732 5.03 0.25 0.25 0.25 0.25 
One arm works, 5 more (50, 50, 50, 
55) 
0.1091 0.1091 NA 0.25 0.25 0.25 0.25 
Better best (50, 55, 60, 65) 0.7953 0.7953 5.11 0.25 0.25 0.25 0.25 
One worse, others work (50, 45, 55, 
60) 
0.6341 0.6341 5.10 0.25 0.25 0.25 0.25 
All work, two similar (50, 55, 60, 
60) 
0.2701 0.2701 5.24 0.25 0.25 0.25 0.25 
        
Design 3 Arm dropping every 50 patients 
Null (50, 50, 50, 50) 0.0025 0.0025 NA 0.36 0.21 0.21 0.21 
One arm works, 10 more (50, 50, 
50, 60) 
0.6919 0.6919 3.68 0.40 0.11 0.11 0.39 
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One arm works, 5 more (50, 50, 50, 
55) 
0.0624 0.0624 NA 0.39 0.13 0.13 0.35 
Better best (50, 55, 60, 65) 0.6843 0.6843 4.16 0.37 0.10 0.19 0.34 
One worse, others work (50, 45, 55, 
60) 
0.6123 0.6123 3.86 0.38 0.07 0.18 0.36 
All work, two similar (50, 55, 60, 
60) 
0.2692 0.2692 3.87 0.36 0.11 0.27 0.26 
        
Design 4 RAR every 50 patients, control matched to best arm 
Null (50, 50, 50, 50) 0.0022 0.0022 NA 0.33 0.22 0.22 0.22 
One arm works, 10 more (50, 50, 
50, 60) 
0.796 0.796 3.56 0.39 0.11 0.11 0.39 
One arm works, 5 more (50, 50, 50, 
55) 
0.0733 0.0733 NA 0.37 0.14 0.14 0.35 
Better best (50, 55, 60, 65) 0.8177 0.8177 4.05 0.36 0.11 0.19 0.35 
One worse, others work (50, 45, 55, 
60) 
0.6872 0.6872 3.67 0.38 0.07 0.18 0.37 
All work, two similar (50, 55, 60, 
60) 
0.2744 0.2744 3.73 0.35 0.12 0.27 0.27 
        
Design 5 RAR every 50 patients, control fixed allocation of 40%  
Null (50, 50, 50, 50) 0.0015 0.0015 NA 0.37 0.21 0.21 0.21 
One arm works, 10 more (50, 50, 
50, 60) 
0.7909 0.7909 3.29 0.36 0.10 0.10 0.44 
One arm works, 5 more (50, 50, 50, 
55) 
0.0677 0.0677 NA 0.37 0.13 0.13 0.37 
Better best (50, 55, 60, 65) 0.8069 0.8069 3.86 0.36 0.10 0.18 0.37 
One worse, others work (50, 45, 55, 
60) 
0.6856 0.6856 3.43 0.36 0.07 0.17 0.40 
All work, two similar (50, 55, 60, 
60) 
0.2744 0.2744 3.54 0.37 0.10 0.26 0.27 
        
Design 6 RAR every 50 patients, no control arm 
Null (50, 50, 50, 50) 0.0117 0.0117 NA 0.25 0.25 0.25 0.25 
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One arm works, 10 more (50, 50, 
50, 60) 
0.9972 0.9972 2.34 0.13 0.13 0.13 0.61 
One arm works, 5 more (50, 50, 50, 
55) 
0.5654 0.5654 NA 0.15 0.15 0.15 0.54 
Better best (50, 55, 60, 65) 0.8982 0.8982 1.95 0.07 0.10 0.22 0.61 
One worse, others work (50, 45, 55, 
60) 
0.8972 0.8972 1.95 0.10 0.07 0.22 0.61 
All work, two similar (50, 55, 60, 
60) 
0.5493 0.5493 2.93 0.06 0.12 0.41 0.41 
aEach row represents a different scenario for each design where the assumed FAOS QoL score is given in brackets as tubular bandage, boot, brace and below-knee cast score 
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Table 4. Summary of re-executions of CAST study using each Bayesian design 
 Design 1 Design 2 Design 3 Design 4 Design 5 Design 6 
Proportion stopping for 
efficacy at 200 patients 
 
NA 0.216 0.148 0.166 0.147 0.072 
Proportion stopping for 
efficacy at 400 patients 
 
NA 0.043 0.011 0.017 0.011 0.004 
Proportion stopping for futility 
at 200 patients 
 
NA 0 0 0 0 0 
Proportion stopping for futility 
at 400 patients 
 
NA 0 0 0 0 0 
Proportion re-executions 
declared successful at final 
analysis 
 
0.855 0.894 0.835 0.865 0.877 0.23 
Proportion re-executions 
tubular bandage (control) 
declared best at final analysis 
 
0 0 0.001 0 0 0 
Proportion re-executions boot 
declared best at final analysis 
 
0.054 0.057 0.085 0.036 0.021 0.007 
Proportion re-executions brace 
declared best at final analysis 
 
0.437 0.402 0.43 0.451 0.481 0.432 
Proportion re-executions 
below-knee cast declared best 
at final analysis 
 
0.509 0.541 0.484 0.513 0.498 0.561 
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Median (IQR) of the posterior 
mean estimates for tubular 
bandage 
 
54.25 (52.70, 
55.68) 
 
53.72 (51.90, 
55.46) 
 
54.40 (52.99, 
55.74) 
 
53.91 (52.52, 
55.30) 
 
53.97 
(52.64, 
55.33) 
52.49 (51.68, 
52.96) 
 
Median (IQR)  of the posterior 
estimates of the difference in 
means between boot and 
tubular bandage 
 
5.60 (3.65, 
7.48) 
 
6.00 (4.02, 
8.25) 
 
5.65 (3.75, 
7.56) 
 
4.77 (2.42, 
6.84) 
 
4.85 (2.58, 
7.05) 
6.42 (3.98, 
8.15) 
 
Median (IQR)  of the posterior 
estimates of the difference in 
means between brace and 
tubular bandage 
 
8.60 (6,52, 
10.63) 
 
8.66 (6.67, 
10.89) 
 
7.62 (4.81, 
10.22) 
 
8.48 (5.65, 
10.71) 
 
8.67 (5.99, 
10.73) 
9.64 (6.01, 
11.66) 
 
Median (IQR)  of the posterior 
estimates of the difference in 
means between below knee 
cast and tubular bandage 
8.70 (6.86, 
10.91) 
 
9.69 (7.22, 
13.29) 
 
8.06 (5.44, 
10.53) 
 
8.79 (6.57, 
11.39),  
8.68 (6.58, 
11.27) 
10.57 (8.69, 
11.78)  
  
 
